Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: PLY011
MIFTS: 63

Polycystic Ovary Syndrome

Categories: Rare diseases, Endocrine diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Polycystic Ovary Syndrome

About this section

MalaCards integrated aliases for Polycystic Ovary Syndrome:

Name: Polycystic Ovary Syndrome 38 12 25 37 55 43 44 15 73
Polycystic Ovarian Syndrome 76 53 25
Polycystic Ovaries 12 29 55
Pcos 12 53 25
Polycystic Ovarian Disease 12 25
Stein-Leventhal Syndrome 12 25
Sclerocystic Ovaries 25 73
Multicystic Ovaries 12 25
Polycystic Ovary Syndrome, Susceptibility to 6
Sclerocystic Ovarian Degeneration 25
Sclerocystic Ovary Syndrome 25
Cystic Disease of Ovaries 25
Cystic Disease of Ovary 25
Stein-Leventhal Synd. 12
Polycystic Ovary 12
Pcod 25
Pco 25

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Endocrine diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:11612
ICD10 33 E28.2
ICD9CM 35 256.4
MeSH 44 D011085
NCIt 50 C26862
KEGG 37 H01739
Sources

Summaries for Polycystic Ovary Syndrome

About this section
MedlinePlus : 43 Polycystic ovary syndrome (PCOS) happens when a woman's ovaries or adrenal glands produce more male hormones than normal. PCOS causes cysts (fluid-filled sacs) to grow on the ovaries. Symptoms include Irregular menstrual periods Infertility Pelvic pain Excess hair growth on the face, chest, stomach, or thighs Weight gain Acne or oily skin Patches of thickened skin Women with PCOS are at higher risk of diabetes, metabolic syndrome, heart disease, and high blood pressure. PCOS is more common in women who have obesity, or have a mother or sister with PCOS. To diagnose PCOS, your health care provider may do a physical exam, pelvic exam, blood tests, and an ultrasound. There is no cure, but diet, exercise, and medicines can help control the symptoms. Birth control pills help women have normal periods, reduce male hormone levels, and clear acne. Treatments for infertility caused by PCOS may include medicines, surgery, and in vitro fertilization (IVF). NIH: National Institute of Child Health and Human Development

MalaCards based summary : Polycystic Ovary Syndrome, also known as polycystic ovarian syndrome, is related to aromatase deficiency and glucose intolerance, and has symptoms including pelvic pain An important gene associated with Polycystic Ovary Syndrome is ENSG00000234940 (
It may contribute to the occurrence of PCOS and affect oocyte development.
Dysfunction Pattern: Regulation), and among its related pathways/superpathways are Glucose / Energy Metabolism and HIF-1 signaling pathway. The drugs Metformin and Cyproterone Acetate have been mentioned in the context of this disorder. Affiliated tissues include ovary, heart and skin, and related phenotypes are homeostasis/metabolism and endocrine/exocrine gland

NIH Rare Diseases : 53 Polycystic ovarian syndrome (PCOS) is a health problem that can affect a woman's menstrual cycle, ability to have children, hormones, heart, blood vessels, and appearance. Women with this condition typically have high levels of  hormones called androgens, missed or irregular periods, and many small cysts in their ovaries. The cause of PCOS is unknown, but probably involves a combination of genetic and environmental factors. Treatment for PCOS may involve birth control pills and medications for diabetes and infertility. Medicines called anti-androgens are also used to speed the growth of hair and clear acne.

Genetics Home Reference : 25 Polycystic ovary syndrome is a condition that affects women in their child-bearing years and alters the levels of multiple hormones, resulting in problems affecting many body systems.

Disease Ontology : 12 A syndrome characterized by hyperandrogenism, polycystic ovaries, hirsutism, oligomenorrhea or amenorrhea, anovulation and excessive body weight.

Wikipedia : 76 Polycystic ovary syndrome (PCOS) is a set of symptoms due to elevated androgens (male hormones) in... more...

Sources

Related Diseases for Polycystic Ovary Syndrome

About this section

Diseases in the Polycystic Ovary Syndrome family:

Polycystic Ovary Syndrome 1

Diseases related to Polycystic Ovary Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 202)
# Related Disease Score Top Affiliating Genes
1 aromatase deficiency 33.1 CYP19A1 GNRH1 INS
2 glucose intolerance 31.6 IGF1 INS INSR SHBG
3 gestational diabetes 31.4 CAPN10 INS INSR SHBG
4 amenorrhea 31.4 GNRH1 PRL SHBG
5 hyperinsulinism 31.3 IGF1 INS INSR SHBG
6 ovarian disease 31.2 CYP11A1 CYP19A1 GDF9 GNRH1 IGF1 INS
7 insulin-like growth factor i 31.1 IGF1 INS INSR PRL SHBG
8 acanthosis nigricans 31.1 IGF1 INS INSR PRL SHBG
9 androgenic alopecia 31.0 CYP19A1 PRL SHBG
10 hyperprolactinemia 31.0 GNRH1 IGF1 PRL SHBG
11 breast disease 30.9 IGF1 PRL SHBG
12 anovulation 30.8 CYP19A1 GNRH1 IGF1 INS PRL SHBG
13 precocious puberty 30.8 CYP19A1 CYP21A2 GNRH1
14 central precocious puberty 30.7 GNRH1 IGF1
15 acromegaly 30.6 IGF1 INS PRL
16 transsexualism 30.6 CYP17A1 CYP19A1 CYP21A2
17 diabetes mellitus, noninsulin-dependent 30.5 CAPN10 GAS5 IGF1 INS INSR SHBG
18 hyperglycemia 30.4 IGF1 INS INSR
19 diabetes mellitus 30.2 CAPN10 IGF1 INS INSR SHBG
20 premature ovarian failure 1 30.2 CYP11A1 CYP19A1 GDF9 GNRH1 PRL SHBG
21 lipoid congenital adrenal hyperplasia 30.1 CYP11A1 CYP17A1 CYP19A1 CYP21A2
22 hyperandrogenism 29.9 CYP17A1 CYP19A1 CYP21A2 GNRH1 IGF1 INS
23 estrogen excess 29.8 CYP19A1 SHBG
24 endometrial cancer 28.9 CYP19A1 GAS5 GNRH1 IGF1 INS SHBG
25 polycystic ovary syndrome 1 12.3
26 cortisone reductase deficiency 11.3
27 classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency 11.3
28 hair-an syndrome 11.2
29 insulin autoimmune syndrome 11.0 INS INSR
30 acth-independent macronodular adrenal hyperplasia 11.0
31 ovarian cyst 11.0
32 secondary adrenal insufficiency 10.9 IGF1 INS
33 galactorrhea 10.9 IGF1 PRL
34 oocyte maturation defect 1 10.9 CYP19A1 FST
35 hypoactive sexual desire disorder 10.9 CYP19A1 SHBG
36 pineal hyperplasia, insulin-resistant diabetes mellitus, and somatic abnormalities 10.8 IGF1 INS INSR
37 sheehan syndrome 10.8 IGF1 INS PRL
38 hyperpituitarism 10.8 IGF1 INS PRL
39 donohue syndrome 10.8 IGF1 INS INSR
40 androgen insensitivity, partial 10.8 CYP19A1 SHBG
41 pseudohypoparathyroidism, type ia 10.8 IGF1 PRL
42 fetal macrosomia 10.8 IGF1 INS INSR
43 pituitary apoplexy 10.8 GNRH1 INS PRL
44 endometriosis of uterus 10.8 GNRH1 PRL
45 thyroid gland disease 10.8 IGF1 INS PRL
46 hypogonadotropism 10.7 GNRH1 PRL
47 overnutrition 10.7 IGF1 INS SHBG
48 hyperthyroidism 10.7 INS PRL SHBG
49 gynecomastia 10.7 CYP19A1 PRL SHBG
50 cell type benign neoplasm 10.7 IGF1 INS PRL

Graphical network of the top 20 diseases related to Polycystic Ovary Syndrome:



Diseases related to Polycystic Ovary Syndrome
Sources

Symptoms & Phenotypes for Polycystic Ovary Syndrome

About this section

UMLS symptoms related to Polycystic Ovary Syndrome:


pelvic pain

MGI Mouse Phenotypes related to Polycystic Ovary Syndrome:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.03 GNRH1 CAPN10 IGF1 CYP11A1 INS CYP17A1
2 endocrine/exocrine gland MP:0005379 10.02 CAPN10 IGF1 CYP11A1 INS INSR CYP19A1
3 adipose tissue MP:0005375 9.85 CAPN10 IGF1 INS CYP17A1 INSR CYP19A1
4 liver/biliary system MP:0005370 9.7 CAPN10 CYP11A1 INS INSR CYP19A1 PRL
5 renal/urinary system MP:0005367 9.5 CAPN10 IGF1 INS CYP17A1 INSR CYP19A1
6 reproductive system MP:0005389 9.32 IGF1 CYP11A1 INS CYP17A1 INSR CYP19A1
Sources

Drugs & Therapeutics for Polycystic Ovary Syndrome

About this section

Drugs for Polycystic Ovary Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 344)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 657-24-9 14219 4091
2
Cyproterone Acetate Approved, Investigational Phase 4,Phase 2,Phase 3,Early Phase 1,Not Applicable 427-51-0
3
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-28-2 5757
4 Estradiol valerate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 979-32-8
5
Ethinyl Estradiol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 57-63-6 5991
6
Polyestradiol phosphate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 28014-46-2
7
Orlistat Approved, Investigational Phase 4,Phase 2,Not Applicable 96829-58-2 3034010
8
Ganirelix Approved Phase 4,Early Phase 1 123246-29-7, 124904-93-4 25081094
9
Drospirenone Approved Phase 4,Phase 3,Phase 1,Not Applicable 67392-87-4 68873
10
Hydrocortisone Approved, Vet_approved Phase 4,Not Applicable,Early Phase 1 50-23-7 5754
11
Pioglitazone Approved, Investigational Phase 4,Not Applicable,Early Phase 1 111025-46-8 4829
12
Simvastatin Approved Phase 4,Phase 3,Not Applicable 79902-63-9 54454
13
Menotropins Approved Phase 4,Phase 2,Phase 1,Not Applicable 61489-71-2, 9002-68-0 5360545
14
Progesterone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable,Early Phase 1 57-83-0 5994
15
Zinc Approved, Investigational Phase 4,Early Phase 1,Not Applicable 7440-66-6 23994
16
Letrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 112809-51-5 3902
17
Resveratrol Approved, Experimental, Investigational Phase 4,Phase 1,Not Applicable 501-36-0 445154
18
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-22-0 6013
19
Medroxyprogesterone acetate Approved, Investigational Phase 4,Phase 3,Phase 1,Not Applicable 71-58-9
20
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
21
Acetylcysteine Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 616-91-1 12035
22
Liraglutide Approved Phase 4 204656-20-2 44147092
23
Citalopram Approved Phase 4 59729-33-8 2771
24
Epinephrine Approved, Vet_approved Phase 4,Not Applicable,Early Phase 1 51-43-4 5816
25
Racepinephrine Approved Phase 4,Not Applicable,Early Phase 1 329-65-7 838
26
Rosiglitazone Approved, Investigational Phase 4,Not Applicable 122320-73-4 77999
27
Leuprolide Approved, Investigational Phase 4,Phase 2,Not Applicable,Early Phase 1 53714-56-0 3911 657181
28
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
29
Hydroxocobalamin Approved Phase 4,Not Applicable 13422-51-0 11953898 44475014
30
Alogliptin Approved Phase 4 850649-61-5 11450633
31
Isotretinoin Approved Phase 4 4759-48-2 5538 5282379
32
Acarbose Approved, Investigational Phase 4,Not Applicable 56180-94-0 441184
33
Tamoxifen Approved Phase 4 10540-29-1 2733526
34
Exenatide Approved, Investigational Phase 4,Phase 3,Phase 2 141758-74-9 15991534
35
Desogestrel Approved Phase 4,Phase 3 54024-22-5 40973
36
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
37
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
38
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 77-92-9 311
39
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 59-30-3 6037
40
leucovorin Approved, Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 58-05-9 143 6006
41
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-14-6 5280793
42
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1406-16-2
43
Vitamin D3 Approved, Nutraceutical Phase 4,Phase 3,Not Applicable 67-97-0 6221 5280795
44
Melatonin Approved, Nutraceutical, Vet_approved Phase 4,Not Applicable 73-31-4 896
45
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
46
Nicotinamide Approved, Investigational, Nutraceutical Phase 4 98-92-0 936
47
Cyanocobalamin Approved, Nutraceutical Phase 4,Not Applicable 68-19-9 44176380
48
Manganese Approved, Nutraceutical Phase 4 7439-96-5 27854
49
Methylcobalamin Approved, Experimental, Investigational, Nutraceutical Phase 4,Not Applicable 13422-55-4
50
Inulin Approved, Investigational, Nutraceutical Phase 4 9005-80-5 24763

Interventional clinical trials:

(show top 50) (show all 569)
# Name Status NCT ID Phase Drugs
1 Therapeutic Monitoring of Metformin in Women With Polycystic Ovary Syndrome Unknown status NCT01366391 Phase 4 Metformin
2 the Effect of Diane-35 Pretreatment on In-vitro Fertilization Outcome for Patients With Polycystic Ovary Syndrome Unknown status NCT01752270 Phase 4 Diane-35 pretreatment;Diane-35 pretreatment
3 The Effect of Weight Loss on Anti-Müllerian Hormone Levels in Women With Polycystic Ovary Syndrome (PCOS) Unknown status NCT01475019 Phase 4 Orlistat;Sibutramine
4 Surgical Ovarian Drilling Versus Hormonal Treatment for Infertility Associated to PolyCystic Ovaries Syndrome (PCOS) Unknown status NCT00378729 Phase 4 Metformin and FSHr
5 Strategies for Ovulation Induction in Anovulatory Infertile Patients With PCOS Unknown status NCT00461643 Phase 4 Clomiphene citrate, metformin, metformin plus clomiphene citrate, gonadotropins
6 Metformin in Infertile PCOS Patients Unknown status NCT00501904 Phase 4 Metformin
7 Endometrial Scratching During Laproscopic Ovarian Drilling in Subfertile PCOS Women Unknown status NCT02140398 Phase 4
8 Myoinositol for the Treatment of Ovarian and Psychiatric Disorder in Polycystic Ovary Syndrome (PCOS) Patients Unknown status NCT01246310 Phase 4
9 PCOS, Therapy and Markers of Cardiovascular Risk Unknown status NCT01798875 Phase 4 oral metformin;oral contraceptive
10 Metformin in Step-down Regimen Versus Conventional Low Dose Step-up Protocol in Patients With PCOS Undergoing IVF Unknown status NCT01438190 Phase 4 Metformin, gonadotropins in step-down regimen;Placebo, gonadotropins in step-up regimen
11 Metformin and Gestational Diabetes in High-risk Patients: a RCTs Unknown status NCT00883259 Phase 4 Metformin
12 Comparison Between GnRH Agonist and GnRH Antagonist Protocols of Ovarian Stimulation in PCOS Patients Unknown status NCT00417144 Phase 4 Arvekap 0.1mg (Triptorelin, Ipsen, France);Ganirelix 0.25mg (Orgalutran, Organon, The Netherlands)
13 Adding L-carnitine in Clomiphene Resistant Polycystic Ovary Improves the Quality of Ovulation and the Pregnancy Outcome Unknown status NCT01665547 Phase 4 l-carnitine
14 Hemocoagulation and Lipoperoxidation in Women Using Combined Oral Contraceptives, Correction by Antioxidants Unknown status NCT02027337 Phase 4 20 mcg ethinylestradiol /3 mg drospirenone;20 mcg ethinylestradiol/3 mg drospirenone and Selmevit;30 mcg ethinylestradiol/3 mg drospirenone;30 mcg ethinylestradiol/3 mg drospirenone and Selmevit;35 mcg ethinylestradiol/2 mg cyproterone;35 mcg ethinylestradiol/2 mg cyproterone and Selmevit
15 Corifollitropin Alfa Application in PCOS Patients Unknown status NCT02215135 Phase 4 Corifollitropin alfa
16 Metformin for the Treatment of Unexplained Oligozspermia Unknown status NCT01529177 Phase 4 Metformin / clomid / hCG;Clomiphene citrate / hCG
17 Efficacy of Corifollitropin Alfa in Obese Women in Terms of Clinical and Molecular Parameters of IVF Success Unknown status NCT02606500 Phase 4 Elonva
18 Polycystic Ovary Syndrome - Improving Outcomes Completed NCT01504321 Phase 4 Moxonidine;Placebo
19 N-acetyl Cysteine for Ovulation Induction in Clomiphene Citrate Resistant Polycystic Ovary Syndrome Completed NCT02239107 Phase 4 N-Acetyl cysteine
20 Metformin and Lifestyle Intervention in Women With Polycystic Ovary Syndrome Completed NCT00679679 Phase 4 Metformin;Placebo
21 Trial With Metformin in Women With Polycystic Ovary Syndrome Completed NCT02280057 Phase 4 Metformin;Placebo
22 PCOSMIC Trial - PolyCystic Ovary Syndrome, Metformin for Infertility With Clomiphene Completed NCT00795808 Phase 4 Metformin;Placebo;Metformin + Clomiphene;Metformin;Clomiphene
23 Effect of Nicotinic Acid on Cardiovascular Risks Indices in Polycystic Ovary Syndrome Completed NCT01118598 Phase 4 tredaptive (nicotinic acid/ laropiprant);placebo
24 The Effects of Fish Oils on Blood Pressure, Heart Rate Variability and Liver Fat in the Polycystic Ovary Syndrome Completed NCT00620529 Phase 4
25 Low Dose OC Therapy in Women With Polycystic Ovary Syndrome (PCOS): Impact of BMI on Hyperandrogenism Completed NCT01360996 Phase 4 3 mg DRSP/20 μg EE
26 LIPT - Liraglutide in Polycystic Ovary Syndrome Completed NCT02073929 Phase 4 Liraglutide;placebo
27 The Effects of Vitamin D on Transforming Growth Factor-beta1 in Polycystic Ovary Syndrome Completed NCT02460380 Phase 4 Vitamin D3
28 The Effect of Ethinyl Estradiol on Polycystic Ovary Syndrome Women Undergoing Intrauterine Insemination Completed NCT01219101 Phase 4 clomiphene citrate with ethinyl esteradiol;clomiphene citrate with plasebo
29 Metformin and Folate Supplementation in Polycystic Ovary Syndrome (PCOS) Patients Completed NCT00953355 Phase 4 Folate plus metformin;Placebo plus metformin
30 Short-term Structured Exercise Training Program Plus Diet Intervention in Patients With Polycystic Ovary Syndrome (PCOS) Completed NCT01004068 Phase 4 Clomiphene citrate
31 Pioglitazone Treatment in Polycystic Ovary Syndrome Completed NCT00145340 Phase 4 pioglitazone
32 Polycystic Ovary Syndrome and Liraglutide Completed NCT01899430 Phase 4 liraglutide;metformin
33 Metformin and Folate in Pregnant Polycystic Ovary Syndrome(PCOS) Women Completed NCT01115140 Phase 4 metformin plus placebo;Metformin plus folic acid;placebo plus folic acid;placebo alone
34 The Effect of Cipralex on Quality of Life, Adrenal Activity Glucose Metabolism, Physical and Mental Health in PCOS Completed NCT01961180 Phase 4 Cipralex;Placebo
35 Effects of Metformin Plus Simvastatin on Polycystic Ovarian Syndrome (PCOS): A Prospective, Randomized, Double-Blind, Placebo-Controlled Study Completed NCT01021579 Phase 4 Metformin plus Placebo;Metfomin plus Simvastatin
36 Polycystic Ovary Syndrome and Liraglutide as Add-on Therapy on Metformin Completed NCT01911468 Phase 4 metformin;liraglutide;metformin and liraglutide
37 PDE-4 Inhibitor Roflumilast and Polycystic Ovary Syndrome Completed NCT02037672 Phase 4 metformin;metformin and roflumilast
38 PDE-4 Inhibitor Roflumilast and GLP-1 Agonist Liraglutide in Polycystic Ovary Syndrome Completed NCT02187250 Phase 4 metformin;liraglutide;roflumilast
39 Insulin Resistance, Polycystic Ovary Syndrome, and Bone Research Study Completed NCT00640224 Phase 4 rosiglitazone;drospirenone/ethinyl estradiol
40 Effects of Metformin vs Oral Contraceptives on CV Risk Markers in PCOS Completed NCT00428311 Phase 4 Metformin;Ethynyl-estradiol plus cyproterone acetate
41 Incretin Effect in PCOS Women Completed NCT01892254 Phase 4 Metformin;Placebo
42 Menopur® Versus Follistim® in Polycystic Ovarian Syndrome (PCOS) Completed NCT00805935 Phase 4 Menotropin;Progesterone vaginal insert;Follitropin beta;Progesterone in oil;leuprolide acetate
43 Metformin in High Responder Polycystic Ovary Syndrome (PCOS) Patients Undergoing IVF Cycles Completed NCT01233206 Phase 4 Metformin;Placebo administration
44 Metformin Suspension and Insulin Sensitivity Completed NCT00437333 Phase 4 Metformin cloridrate
45 The Effects of OCP and Metformin on Clinical, Hormonal, Metabolic and Ultrasonographic Characteristics in PCOS Completed NCT02866786 Phase 4 Metformin;ethinyl estradiol and cyproterone acetate
46 Ovarian Stimulation and Intrauterine Insemination in Women With Polycystic Ovarian Syndrome Completed NCT01675843 Phase 4
47 Role of Melatonin Supplementation in Follicular Fluid of in Vitro Fertilization (IVF) Patients With Polycystic Ovarian Syndrome Completed NCT01540747 Phase 4
48 Clinical, Metabolic and Endocrine Effects of the Treatment With Drospirenone and Ethinyl Estradiol Alone or in Combination With Myo-inositol in Young Women With Polycystic Ovary Syndrome (PCOS) and Insulin Resistance Completed NCT01511822 Phase 4 Drospirenone Ethinyl estradiol;Drospirenone Ethinyl estradiol Myo-inositol;placebo
49 Sitagliptin Improved Beta Cell Function and Prevented a Conversion Rate to Impaired Glucose Tolerance and Type 2 Diabetes in Metformin Intolerant Obese Women With Polycystic Ovary Syndrome Completed NCT03122041 Phase 4 Sitagliptin
50 Metformin and Oral Contraceptives in PCOS Completed NCT00451568 Phase 4 Metformin;Desorelle

Search NIH Clinical Center for Polycystic Ovary Syndrome

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: polycystic ovary syndrome

Sources

Genetic Tests for Polycystic Ovary Syndrome

About this section

Genetic tests related to Polycystic Ovary Syndrome:

# Genetic test Affiliating Genes
1 Polycystic Ovaries 29
Sources

Anatomical Context for Polycystic Ovary Syndrome

About this section

MalaCards organs/tissues related to Polycystic Ovary Syndrome:

41
Ovary, Heart, Skin, Liver, Testes, Endothelial, Pituitary
Sources

Publications for Polycystic Ovary Syndrome

About this section

Articles related to Polycystic Ovary Syndrome:

(show top 50) (show all 2923)
# Title Authors Year
1
Correction to: Seyyed Abootorabi et al., The effect of vitamin D supplementation on insulin resistance, visceral fat and adiponectin in vitamin D deficient women with polycystic ovary syndrome: a randomized placebo-controlled trial. ( 29447022 )
2018
2
Ovarian and Extra-Ovarian Mediators in the Development of Polycystic Ovary Syndrome. ( 29941488 )
2018
3
Heterogenous origins of hyperandrogenism in the polycystic ovary syndrome in relation to body mass index and insulin resistance. ( 29068242 )
2018
4
Hyperandrogenism Enhances Muscle Strength After Progressive Resistance Training, Independent of Body Composition, in Women With Polycystic Ovary Syndrome. ( 29927897 )
2018
5
Infertile polycystic ovary syndrome patients undergoing in vitro fertilization with the gonadotropin-releasing hormone-antagonist protocol: role of hyperandrogenism. ( 29376451 )
2018
6
Authors' reply re: Inositol treatment of anovulation in women with polycystic ovary syndrome: a meta-analysis of randomised trials. ( 29226510 )
2018
7
Bariatric Surgery Improves Hyperandrogenism, Menstrual Irregularities, and Metabolic Dysfunction Among Women with Polycystic Ovary Syndrome (PCOS). ( 29500679 )
2018
8
Limitations of insulin resistance assessment in polycystic ovary syndrome. ( 29436386 )
2018
9
Gut Microbial Diversity in Women with Polycystic Ovary Syndrome Correlates with Hyperandrogenism. ( 29370410 )
2018
10
Wilms' Tumor 1 Overexpression in Granulosa Cells Is Associated with Polycystic Ovaries in Polycystic Ovary Syndrome Patients. ( 29414825 )
2018
11
Differential rate in decline in ovarian reserve markers in women with polycystic ovary syndrome compared with control subjects: results of a longitudinal study. ( 29428308 )
2018
12
Evaluation of PCSK9 levels and its genetic polymorphisms in women with polycystic ovary syndrome. ( 29109005 )
2018
13
Abnormality of Klotho Signaling Is Involved in Polycystic Ovary Syndrome. ( 28673204 )
2018
14
Association between Th1/Th2 immune imbalance and obesity in women with or without polycystic ovary syndrome. ( 29447491 )
2018
15
Functional Characterization of MicroRNA-27a-3p Expression in Human Polycystic Ovary Syndrome. ( 29029022 )
2018
16
Differential association of DENND1A genetic variants with polycystic ovary syndrome in Tunisian but not Bahraini Arab women. ( 29325736 )
2018
17
C-type natriuretic peptide: a link between hyperandrogenism and anovulation in a mouse model of polycystic ovary syndrome. ( 29739821 )
2018
18
Hidradenitis suppurativa is associated with polycystic ovary syndrome: a population-based analysis in the United States. ( 29378201 )
2018
19
Serum Levels of Angiopoietin-Like Protein 2 and Obestatin in Iranian Women with Polycystic Ovary Syndrome and Normal Body Mass Index. ( 29932432 )
2018
20
Aerobic Training Improves Quality of Life in Women with Polycystic Ovary Syndrome. ( 29443823 )
2018
21
The use of inositol(s) isomers in the management of polycystic ovary syndrome: a comprehensive review. ( 29309199 )
2018
22
Enlarged adipocytes in subcutaneous adipose tissue associated to hyperandrogenism and visceral adipose tissue volume in women with polycystic ovary syndrome. ( 29273198 )
2018
23
Polycystic Ovary Syndrome in Bipolar Affective Disorder: A Hospital-based Study. ( 29962567 )
2018
24
Lipidomics reveals altered biosynthetic pathways of glycerophospholipids and cell signaling as biomarkers of the polycystic ovary syndrome. ( 29435121 )
2018
25
Fertility management experiences of women with polycystic ovary syndrome in Australia. ( 29939804 )
2018
26
Association of Decreased C1q/Tumor Necrosis Factor-Related Protein-5 Levels with Metabolic and Hormonal Disturbance in Polycystic Ovary Syndrome. ( 29964236 )
2018
27
Association between Major Dietary Patterns and Polycystic Ovary Syndrome: evidence from a case-control study. ( 29969571 )
2018
28
Re: Inositol treatment of anovulation in women with polycystic ovary syndrome: a meta-analysis of randomised trials. ( 29210151 )
2018
29
Non-targeted profiling of circulating microRNAs in women with polycystic ovary syndrome (PCOS): effects of obesity and sex hormones. ( 29410349 )
2018
30
Ovary stereological features and serum biochemical factors following induction of polycystic ovary syndrome with testosterone enanthate in mice: An experimental study. ( 29942935 )
2018
31
Polycystic ovary syndrome in mitochondrial disorders due mtDNA or nDNA variants. ( 29422990 )
2018
32
Polymorphisms in the TFAM and PGC1-I+ genes and their association with polycystic ovary syndrome among South Indian women. ( 29030253 )
2018
33
Abnormal irisin level in serum and endometrium is associated with metabolic dysfunction in polycystic ovary syndrome patients. ( 29972694 )
2018
34
Association between depression, symptom experience and quality of life in polycystic ovary syndrome. ( 29969586 )
2018
35
The Role of C-Peptide as Marker of Cardiometabolic Risk in Women With Polycystic Ovary Syndrome: A Controlled Study. ( 29416587 )
2018
36
The preliminary association study of ADIPOQ, RBP4, and BCMO1 variants with polycystic ovary syndrome and with biochemical characteristics in a cohort of Polish women. ( 29428584 )
2018
37
Thymoquinone ameliorates some endocrine parameters and histological alteration in a rat model of polycystic ovary syndrome. ( 29942936 )
2018
38
A Retrospective Study of Letrozole Treatment Prior to Human Chorionic Gonadotropin in Women with Polycystic Ovary Syndrome Undergoing In Vitro Fertilization at Risk of Ovarian Hyperstimulation Syndrome. ( 29925074 )
2018
39
Circulating insulin-like peptide 5 levels and its association with metabolic and hormonal parameters in women with polycystic ovary syndrome. ( 29956214 )
2018
40
Improving care for women with polycystic ovary syndrome. ( 29933923 )
2018
41
Impact of cancer treatment on risk of infertility and diminished ovarian reserve in women with polycystic ovary syndrome. ( 29428311 )
2018
42
High-molecular-weight adiponectin is inversely associated with sympathetic activity in polycystic ovary syndrome. ( 29428305 )
2018
43
Effects of combined oral contraceptives on the clinical and biochemical parameters of hyperandrogenism in patients with polycystic ovary syndrome: a systematic review and meta-analysis. ( 29457756 )
2018
44
The numbers of 2- 5 and 6-9 mm ovarian follicles are inversely correlated in both normal women and in polycystic ovary syndrome patients: what is the missing link? ( 29425289 )
2018
45
Effect of exposure to second-hand smoke from husbands on biochemical hyperandrogenism, metabolic syndrome and conception rates in women with polycystic ovary syndrome undergoing ovulation induction. ( 29471520 )
2018
46
Increased odds of disordered eating in polycystic ovary syndrome: a systematic review and meta-analysis. ( 29947018 )
2018
47
Elevated CD14<sup>++</sup>CD16<sup>+</sup>Monocytes in Hyperhomocysteinemia-Associated Insulin Resistance in Polycystic Ovary Syndrome. ( 29439619 )
2018
48
Development of a question prompt listA for women with polycystic ovary syndrome. ( 29960706 )
2018
49
Improvement of hyperandrogenism, oligo-ovulation, and ovarian morphology in a patient with polycystic ovary syndrome: possible role of ovarian wedge resection. ( 29298536 )
2018
50
Unilateral or bilateral laparoscopic ovarian drilling in polycystic ovary syndrome: a meta-analysis of randomized trials. ( 29374790 )
2018
Sources

Variations for Polycystic Ovary Syndrome

About this section

ClinVar genetic disease variations for Polycystic Ovary Syndrome:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 CAPN10 NM_023083.3(CAPN10): c.471-187T> C single nucleotide variant risk factor rs2975760 GRCh37 Chromosome 2, 241531163: 241531163
2 CAPN10 NM_023083.3(CAPN10): c.471-187T> C single nucleotide variant risk factor rs2975760 GRCh38 Chromosome 2, 240591746: 240591746
Sources

Expression for Polycystic Ovary Syndrome

About this section
Search GEO for disease gene expression data for Polycystic Ovary Syndrome.
Sources

Pathways for Polycystic Ovary Syndrome

About this section

Pathways related to Polycystic Ovary Syndrome according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
1
Glucose / Energy Metabolism 4
12.21 CYP11A1 CYP17A1 CYP19A1 INS INSR
2
HIF-1 signaling pathway 37
11.63 IGF1 INS INSR
3
AGE/RAGE pathway 1
11.43 INS INSR MSR1
4
Metabolism of steroid hormones 66
Show member pathways
 11.4 CYP11A1 CYP17A1 CYP19A1 CYP21A2
5
Signaling events mediated by PTP1B 1
11.28 INS INSR PRL
6
Differentiation Pathway 1
11.23 FST IGF1 INS
7
Steroid hormone biosynthesis 37
Show member pathways
 11.07 CYP11A1 CYP17A1 CYP19A1 CYP21A2
8
Aldosterone-regulated sodium reabsorption 37
11 IGF1 INS INSR
9
superpathway of steroid hormone biosynthesis 1
Show member pathways
 10.82 CYP17A1 CYP21A2
10
Ovarian steroidogenesis 37
10.79 CYP11A1 CYP17A1 CYP19A1 IGF1 INS INSR
11
Nongenotropic Androgen signaling 1
10.73 GNRH1 SHBG
Sources

GO Terms for Polycystic Ovary Syndrome

About this section

Cellular components related to Polycystic Ovary Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endosome lumen GO:0031904 8.62 INS PRL

Biological processes related to Polycystic Ovary Syndrome according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.96 GDF9 IGF1 INS INSR PRL
2 regulation of signaling receptor activity GO:0010469 9.92 GDF9 GNRH1 IGF1 INS PRL
3 steroid metabolic process GO:0008202 9.77 CYP11A1 CYP17A1 CYP21A2
4 activation of MAPK activity GO:0000187 9.76 IGF1 INS INSR
5 glucose homeostasis GO:0042593 9.74 IGF1 INS INSR
6 response to nutrient levels GO:0031667 9.69 IGF1 INS PRL
7 positive regulation of DNA replication GO:0045740 9.63 IGF1 INS INSR
8 activation of protein kinase B activity GO:0032148 9.61 IGF1 INS INSR
9 positive regulation of insulin receptor signaling pathway GO:0046628 9.58 IGF1 INS
10 positive regulation of mitotic nuclear division GO:0045840 9.58 IGF1 INS INSR
11 steroid biosynthetic process GO:0006694 9.56 CYP11A1 CYP17A1 CYP19A1 CYP21A2
12 male sex determination GO:0030238 9.55 GNRH1 INSR
13 amyloid-beta clearance GO:0097242 9.54 INSR MSR1
14 positive regulation of glycolytic process GO:0045821 9.54 IGF1 INS INSR
15 positive regulation of glycogen biosynthetic process GO:0045725 9.5 IGF1 INS INSR
16 positive regulation of respiratory burst GO:0060267 9.49 INS INSR
17 neuron projection maintenance GO:1990535 9.48 INS INSR
18 glucocorticoid biosynthetic process GO:0006704 9.33 CYP11A1 CYP17A1 CYP21A2
19 positive regulation of glucose import GO:0046326 9.26 CAPN10 IGF1 INS INSR
20 sterol metabolic process GO:0016125 8.92 CYP11A1 CYP17A1 CYP19A1 CYP21A2

Molecular functions related to Polycystic Ovary Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 iron ion binding GO:0005506 9.62 CYP11A1 CYP17A1 CYP19A1 CYP21A2
2 heme binding GO:0020037 9.56 CYP11A1 CYP17A1 CYP19A1 CYP21A2
3 hormone activity GO:0005179 9.46 GNRH1 IGF1 INS PRL
4 receptor activator activity GO:0030546 9.37 IGF1 INS
5 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen GO:0016705 9.26 CYP11A1 CYP17A1 CYP19A1 CYP21A2
6 insulin-like growth factor receptor binding GO:0005159 8.8 IGF1 INS INSR
Sources

Sources for Polycystic Ovary Syndrome

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....